SUMMARY Ten serum proteins are measured by quantitative immunoelectrophoresis in 20 chronic schizophrenic and nine epileptic patients. Results from each group are compared with each other and with normal values and significant differences noted. Schizophrenic patients had higher haemopexin levels and epileptic patients had higher cx2 group component levels, both compared with normal subjects. Also schizophrenics had higher ot1PGp and ca1AT levels compared with epileptics.
There exist numerous reports of alterations in biochemical parameters among groups of hospitalized schizophrenic patients. Such parameters have included protein levels determined in various ways and probably among differing types of patients, the diagnosis of schizophrenia being an individual decision which is hard to define and which is not always even described. The conflicting reports of abnormalities have not allowed any firmer hypothesis about the pathogenesis of the schizophrenias than existed before investigations into the protein changes in schizophrenia were begun. The controlled study reported here seeks to take into account some of the variables often ignored by other workers, and thus to place on a firmer basis the minor alterations in serum protein levels which have been described.
MATERIALS AND METHODS

PATIENT SELECTION
Two groups of patients were selected on the following criteria.
1. GENERAL All patients were Europeans aged between 20 and 60 years; they had no past history ofjaundice or of general organic disease, and showed no evidence of current organic disease. They were fit for occupational or work therapy. Every patient was able to eat the full ward diet; no food supplements were given. 2. DIAGNOSTIC CRITERIA a. Schizophrenia Schizophrenic symptoms of the first rank (Schneider, 1959) had been detected on admission and could still be elicited when examined by one of us during the selection interview. Evidence of passivity experiences, primary delusions or thought resonance, withdrawal, sharing, or broadcasting were thus required. Selection was made initially from patients already diagnosed independently by other physicians as having paranoid schizophrenia. Symptoms of the second rank, including hallucinations, motor and volitional symptoms, and emotional disturbances with other forms of thought disorder were also recorded in all patients. Those with signs of organic dementia or with affective illness were excluded. Treatment with drugs (apart from monoamine oxidase inhibitors) was not a selection factor. b. Epilepsy All patients had had grand mal attacks or focal seizures including lapses of consciousness, but not true petit mal. All were exhibiting symptoms and signs of the schizophrenia-like psychoses of epilepsy as described by Slater, Beard, and Glithero (1963) . Thus a schizophrenia-like picture, usually without gross affective blunting and with or without signs of organic brain disease, was necessary for inclusion in this group.
3 DATA COLLECTION The patients studied included all those conforming to the selection criteria in a large English mental hospital and in four long-stay wards in a second similar institution. All patients were seen by one of us and information about the past history was recorded from the clinical records onto standard proformas. There followed a diagnostic interview in which the clinical features required for selection were elicited. After selection, an aftemoon venous blood sample was collected without stasis and was separated within four hours of collection.
4 METHODS Sera were stored at -20°C until analysis by the quantitative immunoelectrophoretic technique described by Laurell (1965) and modified by Clarke and Freeman (1968) . Figure 1 shows the type of plate produced by this method; each protein produces a precipitation curve, the area under which is proportional to the quantity of that protein in serum, and inversely proportional to concentration of antibody to that protein. Ten proteins were selected for estimation, and compared with a reference serum. The range for each of these proteins found in a normal European population, using this technique, has been published (Clarke and Freeman, 1968) .
Clinical information, together with protein concentration was coded and transferred to IBM 80 column punched cards for statistical treatment. RESULTS PERSONAL DATA In Table 1 figures being given as percentages of a standard normal serum. It will be seen that the schizophrenic patients studied here have significantly higher haemopexin values than the normal series; while the patients with epilepsy had significantly higher a2 group component levels than the normal subjects and the schizophrenics. The schizophrenic patients also had higher a1PGp and ac1AT levels than the epileptics. Apart from these no other characteristics could be defined. Fessell (1961) and by Seal and Eist (1966) include: (1) increased levels of haptoglobin, orosomucoid, C-reactive protein, rheumatoid factor, combined a, and a2 globulins, globulin, and caeruloplasmin; (2) decreased albumin and transferrin; (3) unaltered caeruloplasmin and a and B lipoproteins.
Some previous findings have been confirmed by our study. The levels of caeruloplasmin detected were reviewed by Fessell (1961) and by Sandor (1966) ; both pointed out that initial findings of a raised caeruloplasmin level in schizophrenia (Abood, Gibbs, and Gibbs, 1957; and Scheinberg, Morel, Harris, and Berger, 1957; Martens, Vallbo, and Melander, 1959; and Saunders and Chipkiewicz, 1959) have not been confirmed more recently. We report normal caeruloplasmin levels in schizophrenic patients. Among females, especially those taking oestrogens, caeruloplasmin levels are higher than in males. The only two females among our nine epileptic subjects had markedly raised caeruloplasmin levels (250% and 172 % reference serum): they were not pregnant, not taking a contraceptive pill, and the changes characteristic of the 'acute phase reaction'
were not present. Abood, Gibbs, and Gibbs (1957) claimed that caeruloplasmin levels were raised within minutes as a response to disturbed behaviour, and among their epileptic patients an abnormally high mean level was detected. Vuyze and Visser (1966) also detected a raised caeruloplasmin level in serum pooled from 10 epileptic patients, while the serum from 10 schizophrenics contained normal amounts. The mean level in our nine epileptic patients was higher than that found either among our normal subjects (though not significant, P = > 0-05) or among the schizophrenic patients studied (P = > 0-05). We have no evidence that recent epileptic attacks, degree of hydration, dietary or hormonal influences, liver disease, or current emotional crises had any influence in either of our groups. Unlike Strisower, DeLalla, Gofman, and Strisower (1957) we found lower levels of ,B lipoprotein (P = > 0 05) in both the schizophrenics and the epileptics than in the normal subjects. We regard this as an artefact, probably due to storage of serum. Seal and Eist (1966) detected raised haptoglobin levels among 60 male schizophrenics, which they suggest might represent a long-term concomitant of the disease. We were not able to confirm these findings.
The raised a, PGp in schizophrenics (P = < 0 05) compared with the normal series, is difficult to explain. a, AT values were also higher (P = < 0 05) among the schizophrenics than among the normal series. While the raised haemopexin values (P = < 0-001) in schizophrenia might be evidence of tissue destruction, haptoglobin values were normal and no clinical evidence would support such a hypothesis. The schizophrenics' raised haemopexin level was significantly above that of the epileptics, which in turn were similarly, but less markedly, raised above normal. Why a heme-binding protein should be elevated is not clear.
In conclusion, there were raised mean values for a, PGp and a, AT (P = < 0-05) and haemopexin (P = < 0-001) among our 19 schizophrenics, but the control group of epileptics had normal mean values apart from a high a GC (P = < 0-01). We regard these abnormalities as valid, although unexplained, characteristics of our chronic paranoid schizophrenic population.
